To explore the RNA-binding proteins (RBPs) involved in the development of CDK4/6i resistance, we analyzed microarray data of ER + breast cancer tissues from patients with palbociclib plus anastrozole (an endocrine therapy drug) treatment (NeoPalAna) (28). Here, CDK4 is linked to breast cancer.